{"id":"fluticasone-evohaler","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Oropharyngeal candidiasis"},{"rate":"5-10","effect":"Hoarseness"},{"rate":"1-5","effect":"Tremor"},{"rate":"5-10","effect":"Headache"},{"rate":"1-5","effect":"Palpitations"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fluticasone propionate is a potent inhaled corticosteroid that acts as a glucocorticoid receptor agonist in airway tissues. It suppresses the production of inflammatory cytokines, chemokines, and adhesion molecules, reducing airway inflammation, mucus production, and bronchial hyperresponsiveness. The Evohaler is a metered-dose inhaler formulation designed for direct delivery to the lungs.","oneSentence":"Fluticasone is a corticosteroid that reduces inflammation in the airways by binding to glucocorticoid receptors and suppressing inflammatory mediator release.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:46:43.840Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Asthma maintenance therapy"},{"name":"Chronic obstructive pulmonary disease (COPD)"}]},"trialDetails":[{"nctId":"NCT03199976","phase":"PHASE4","title":"Efficacy of Intermittent Tiotropium in Early Childhood Wheezing","status":"TERMINATED","sponsor":"Helsinki University Central Hospital","startDate":"2016-04-20","conditions":"Wheezy Bronchitis, Asthmatic Bronchitis, Wheezing","enrollment":80},{"nctId":"NCT02232087","phase":"PHASE1","title":"Single Blind Cross-over Dose Response Study in Subjects of Two Inhalers of Salmeterol and Fluticasone Propionate","status":"COMPLETED","sponsor":"Kindeva Drug Delivery","startDate":"2014-07","conditions":"Healthy","enrollment":52},{"nctId":"NCT04946630","phase":"NA","title":"Explorative Clinical Investigation to Investigate the Ability of PreciseInhale to Direct Regional Lung Targeting and Reduce the Degree of Throat Deposition and Subsequent Gastrointestinal Absorption in Healthy Volunteers After Inhalation of Test Drug Substances Via the PreciseInhale System","status":"COMPLETED","sponsor":"Inhalation Sciences Sweden AB","startDate":"2021-06-07","conditions":"Nebulizers and Vaporizers","enrollment":12},{"nctId":"NCT05054322","phase":"PHASE2, PHASE3","title":"FLuticasone in cOvid Treatment (FLOT)","status":"UNKNOWN","sponsor":"University of Medicine and Pharmacy at Ho Chi Minh City","startDate":"2021-09-22","conditions":"Covid19","enrollment":500},{"nctId":"NCT01933984","phase":"NA","title":"Individualized Dosing Schedule of Inhaled Bronchodilator for Endotracheally Intubated COPD Patients","status":"COMPLETED","sponsor":"Shin-hwar Wu","startDate":"2013-08","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":51},{"nctId":"NCT00903227","phase":"PHASE4","title":"Steroid Sparing Effect of Nasal Corticosteroid In Asthma And Rhinitis","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2006-12","conditions":"Asthma, Allergic Rhinitis","enrollment":25},{"nctId":"NCT01388595","phase":"PHASE4","title":"Fluticasone and Salmeterol in Allergic Rhinitis","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2006-11","conditions":"Allergic Rhinitis","enrollment":23},{"nctId":"NCT01194700","phase":"PHASE4","title":"Comparative Study of Lung Bioavailability of HFA-Seretide Via Current Spacer Devices in Healthy Volunteers","status":"COMPLETED","sponsor":"Brian J Lipworth","startDate":"2009-11","conditions":"Asthma","enrollment":19},{"nctId":"NCT02045953","phase":"PHASE1","title":"A Study to Assess the Systemic Exposure of FLIXOTIDE™ (Fluticasone Propionate) and SERETIDE™ (Fluticasone Propionate and Salmeterol) Given With VENTOLIN™ Mini-Spacer Compared to the Aerochamber Plus Spacer","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-01-29","conditions":"Asthma","enrollment":21},{"nctId":"NCT02416180","phase":"PHASE4","title":"Study to Evaluate Handling Errors in Usage of SERETIDE® Metered Dose Inhaler (MDI) (EVOHALER®) by Adult Subjects Currently Using the SERETIDE DISKUS® Inhaler","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-06-18","conditions":"Asthma","enrollment":111},{"nctId":"NCT01070524","phase":"PHASE2","title":"Cross-over Study to Evaluate the Effect on Trough Forced Expiratory Volume in One Second (FEV1) After 4 Weeks Treatment With CHF 5188 pMDI qd in Adult Patients With Persistent Asthma","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2010-01","conditions":"Asthma","enrollment":113},{"nctId":"NCT02466347","phase":"PHASE1","title":"Bioequivalence Study of Synflutide HFA Inhaler and Seretide Evohaler in Healthy Volunteers Without Charcoal Block","status":"COMPLETED","sponsor":"Intech Biopharm Ltd.","startDate":"2014-06","conditions":"Asthma, Chronic Obstructive Pulmonary Disease (COPD)","enrollment":45},{"nctId":"NCT02388373","phase":"PHASE4","title":"A Guideline Approach to Therapy Step-down Utilising Flutiform Change and Step-down","status":"COMPLETED","sponsor":"Research in Real-Life Ltd","startDate":"2014-07","conditions":"Asthma","enrollment":225},{"nctId":"NCT02546349","phase":"PHASE4","title":"Exhaled NO Based Treatment of Chronic Obstructive Pulmonary Disease (COPD), ICS/LABA Versus LAMA","status":"UNKNOWN","sponsor":"Taipei Veterans General Hospital, Taiwan","startDate":"2014-07","conditions":"COPD","enrollment":143},{"nctId":"NCT02466503","phase":"PHASE1","title":"Bioequivalence Study of Synflutide HFA Inhaler and Seretide Evohaler in Healthy Volunteers With Charcoal Block","status":"COMPLETED","sponsor":"Intech Biopharm Ltd.","startDate":"2014-08","conditions":"Asthma, Chronic Obstructive Pulmonary Disease (COPD)","enrollment":45},{"nctId":"NCT01795664","phase":"PHASE3","title":"Compare the Effects of Seretide® Evohaler and a Generic Salmeterol/Fluticasone Hydrofluoroalkane (HFA) Pressurized Metered-dose Inhaler (pMDI) on Functional Respiratory Imaging Parameters in Asthmatic Patients","status":"COMPLETED","sponsor":"FLUIDDA nv","startDate":"2013-03","conditions":"Asthma","enrollment":16},{"nctId":"NCT01274325","phase":"PHASE3","title":"Comparison of Anti-inflammatory Effects of Seroflo and Seretide in Patients With Asthma","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2011-02","conditions":"Asthma","enrollment":51},{"nctId":"NCT00830102","phase":"PHASE2","title":"Single-dose Crossover Study to Compare the Safety and Efficacy of FlutiForm With Fluticasone and Formoterol Concurrently or Alone in Asthma Patients","status":"COMPLETED","sponsor":"SkyePharma AG","startDate":"2004-10","conditions":"Asthma","enrollment":64},{"nctId":"NCT01131806","phase":"PHASE4","title":"Comparing Treatment Efficacy With HD/MD Flu Plus Sal in Chronic Obstructive Pulmonary Disease (COPD) Patients","status":"UNKNOWN","sponsor":"Taipei Veterans General Hospital, Taiwan","startDate":"2009-12","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":124}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":17,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Fluticasone Evohaler","genericName":"Fluticasone Evohaler","companyName":"University of Dundee","companyId":"university-of-dundee","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fluticasone is a corticosteroid that reduces inflammation in the airways by binding to glucocorticoid receptors and suppressing inflammatory mediator release. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}